CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 3, 2018--
Therapeutics, Inc. (Nasdaq:AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia-inducible factor (HIF), granted
five newly-hired employees options to purchase an aggregate of 49,650
shares of Akebia’s common stock on November 30, 2018, as inducements
material to each such employee’s entering into employment with Akebia.
The options were granted in accordance with Nasdaq Listing Rule
The options have an exercise price of $8.08 per share, which is equal to
the closing price of Akebia’s common stock on the grant date. Each stock
option vests over four years, with 25% of the shares vesting on the
first anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee’s continued service with the company. Each stock option has a
10-year term and is subject to the terms and conditions of the company’s
Inducement Award Program and a stock option agreement covering the grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc.is a biopharmaceutical company headquartered in
Cambridge, Massachusetts, focused on delivering innovative therapies to
patients with kidney disease through hypoxia-inducible factor biology.
For more information, please visit our website at www.akebia.com,
which does not form a part of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181203005910/en/
Source: Akebia Therapeutics, Inc.
Melissa Forst /